Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-52

First 52 Last

Share
Profile

Follow
slura

3,799 Posts.

1562

13/10/21

15:14

Post #: 56770489
Share

Originally posted by iken2950: ↑

Arthropharm has an internationally published PPS patent: PCT/AU2021/050215, priority date 12 March 2020 which appears to comprehensively cover the treatment and prevention of acute respiratory distress syndrome (ARDS). The patent’s primary focus seems to be coronavirus, but it also includes “graft versus host disease (GVHD), avian influenza, smallpox, pandemic influenza, adult respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sepsis, and systemic inflammatory response syndrome (SIRS). Their patent includes “any embodiment of the invention, the sulphated polysaccharide, preferably pentosan polysulfate (PPS) administered to the individual intravenously, subcutaneously, orally, intramuscularly, via gastric tube, intranasally or by inhalation”. PAR’s ASX announcement of encouraging results of its “preclinical proof-of-concept model of acute respiratory distress syndrome (ARDS)” suggests PPS may be a useful prevention or treatment, but if publication of the proof-of-concept study captures the interest of pharma, my guess is Arthropharm would be pharma’s first port of call, particularly as Arthropharm already markets PPS (Elmiron) and (Cartrophen). Has PR accidentally done them a favour? Better to keep focussed on getting the OA PPS CT approved and launched.

Expand

Do you have a link to that patent?

PAR Price at posting: $1.89 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint